Kerbside

The recommendations provided in this column are taken from various market sources such as brokers, analysts, dealers and investment strategists, etc. These recommendations may not be backed by strong fundamentals. Therefore we advise readers to use their own discretion before investing in these recommendation .

ON THE FAST TRACK

Balkrishna Industries
BSE Code: 502355
CMP: Rs1269.00

Balkrishna Industries is India’s leading player in the global off-highway tyre (OHT) market. Deep understanding of the PHT market has led it to build capabilities to manufacture over 2,700 SKUs. The company sells its products to over 160 countries through a vast distribution network in Americas, Europe, India and the rest of the world. The management had indicated that they should be able to cross 200,000 MT sales volumes for FY20 and was able to cross this figure with sales volume of 201,760 MT for FY20. This is despite the shutdown of manufacturing operations and dispatches across all their plants due to the pandemic-driven lockdown. Balkrishna Industries has a resilient business model in place and is confident of withstanding near-term challenges to emerge stronger with a higher global market share. Hence, traders with short to medium-term perspective can consider this stock for decent returns.

POISED FOR PROSPERITY

HDFC Life
BSE Code: 540777
CMP: Rs 549.30

There is a strong murmur on Dalal Street that in the semi-annual review of the components of Nifty by exchanges could lead to inclusion of HDFC Life. If this turns out to be true, this stock may witness good inflow. One of the leading broking firms had estimated HDFC Life to post an inflow of USD 100 million with a weight of 99 basis points because of the rebalancing for index funds.

PICKING UP SPEED

Motilal Oswal Financial Services
BSE Code: 532892
CMP: Rs595

Motilal Oswal Financial Services is an Indian diversified financial services firm offering a range of financial products and services. As per our sources and according to the grapevine of the dealers, the stock is posting good accumulation from HNIs in recent days since they are betting on a big announcement to be made soon, which could induce strong momentum in the stock. Further, an ace investor who has a knack for picking up stocks at inflection point is quite bullish about this scrip. Hence, traders and investors with high risk appetite can grab this stock.

ENSURING HEALTHY GROWTH

Cipla
BSE Code: 500087
CMP: Rs627.10

Cipla and Boehringer Ingelheim have forged a partnership to co-market three oral anti-diabetic drugs. With this latest multi-product deal, Cipla will be at the forefront of providing holistic diabetes care. As per the International Diabetes Federation, India is home to 77 million adults aged between 20 and 79 years with diabetes, ranking second behind China, and is poised to reach 134.2 million patients by 2045. Fortunately, while the number of patients is increasing, so is the awareness among the public to address it. The Indian diabetes market is valued at Rs 145,451 million and is growing at 10.35 per cent (IMS MAT, May 2020) with the oral anti-diabetic market being valued at Rs 107,354 million and growing at 11.34 per cent (IMS MAT, May 2020). After this deal the company has placed itself in a sweet spot for growth.

(Closing price as of July 01, 2020)